Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy given permission to appeal Lipitor ruling
In his previous judgment, Justice Pumfrey ruled that Ranbaxy would not be able to distribute its generic version of the world’s best-selling drug in the UK, as the
In his previous judgment, Justice Pumfrey ruled that Ranbaxy would not be able to distribute its generic version of the world’s best-selling drug in the UK, as the
The jury said that the drug was not responsible for the heart attack suffered by the plaintiff, a postal worker from Idaho, US, who suffered the heart attack
Emisphere intends to initiate patient enrollment before the end of November for a 90-day, multi-center, double-blind, randomized clinical trial. The four-arm study will evaluate the safety and efficacy
Under the terms of the agreement, Par will promote Cesamet to physicians in the US, whilst Valeant will record sales of the drug and fund all marketing expenses
Fast track designated therapeutics are eligible for priority review, meaning that the review is completed within six months instead of the customary twelve. Also, the review of portions
The interim analysis from the trial was presented during the thirteenth European Cancer Conference in Paris. More than 900 patients with advanced kidney cancer participated in the international
Tarceva is the first drug in a phase III trial to have shown a significant improvement in overall survival when added to gemcitabine chemotherapy as initial treatment for
According to the company, the project is on track to be the largest drug donation program in global pharmaceutical industry history. The project has the aim of eradicating
J&J claims that the recent recalls have had a material adverse effect on Guidant, and, as a result, that it is not required under the terms of the
The study showed that, after a year, one patient out of every four was still alive when treated with Xeloda plus standard chemotherapy, compared to one in five